1,520.00
1,628.00
1,209.95
1,800.00
1,209.95
1,800.00
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
Current Price
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
Stock PE (TTM)
Promoter Holding
Book Value
ROCE
ROE
Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of `Inbiopro Solutions Private Limited` dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The Company name was then changed to `Stelis Biopharma Private Limited`, pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies. The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as `Stelis Biopharma Limited` dated July 31, 2021,. Subsequently, the name was changed to its present `Onesource Specialty Pharma Limited` on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore. A Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024. Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively. Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, 2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies. In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re. 1/- each have been allotted and issued. At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers end-to-end Contract Development and Manufacturing Operations (CDMO) services across all phases of pre-clinical and clinical development and commercial supply of biologics. Company has 5 globally compliant Manufacturing Facilities. Customer list includes some of the top pharmaceutical generic companies, innovator pharmaceutical and biopharmaceutical companies, small biotechs and dedicated R&D houses, spread across the globe.
OneSource Specialty Pharma share price as on 19 Mar 2025 is Rs. 1597.15. Over the past 6 months, the OneSource Specialty Pharma share price has increased by 0% and in the last one year, it has decreased by 6.6%. The 52-week low for OneSource Specialty Pharma share price was Rs. 1209.95 and 52-week high was Rs. 1800.
544292
ONESOURCE
INE013P01021
You can buy OneSource Specialty Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy OneSource Specialty Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Mar 19, 2025 03:47 PM the closing price of OneSource Specialty Pharma Ltd was Rs.1,597.15.
The latest PE ratio of OneSource Specialty Pharma Ltd as of Mar 19, 2025 03:47 PM is 0.00
The latest PB ratio of OneSource Specialty Pharma Ltd as of Mar 19, 2025 03:47 PM is 0.02
The 52-week high of OneSource Specialty Pharma Ltd share price is Rs. 1,800.00 while the 52-week low is Rs. 1,209.95
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Mar 19, 2025 03:47 PM, the market cap of OneSource Specialty Pharma Ltd stood at Rs. 18,277.15 Cr.
We appreciate your patience. Your content is on the way.